Full Press Release Details
National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies.
CRVO
National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies
Key Takeaway: National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke